Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

MHLW Requires Expert Panel Members To Disclose Special Interests With Makers

This article was originally published in PharmAsia News

Executive Summary

The Advanced Medical Technology Advisory Committee at the Ministry of Health, Labor and Welfare June 17 decided on new rules requiring expert panel members to disclose financial ties with drug or device makers whose products are under review. It ruled that if members or their relatives have received more than ¥5 million in donations or contract payments in the past three years, they should not attend review meetings for the drugs or devices. If the amount is between ¥5 million and ¥500,000, the member is allowed to attend discussion sessions, and below ¥500,000, he or she will be able to attend final summary sessions. MHLW defines the payments as consulting and instruction fees on patent and trademarks, speech fees and authoring compensations. The Ministry asks advisory board members and relatives to self claim the maximum amount received (Click here for more - Japanese language
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC072003

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel